1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK

Journal article

Peer reviewed

S.J. Freedland, M.E. Gleave, U.F.F. De Giorgi, A. Rannikko, C. Pieczonka, S. Sridharan, K. Brasso, H. Woo, A. Gomez Caamaño, J. Saranchuk, …

Annals of oncology, Vol.34, pp.S961-S961

10/2023

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2023.09.2728View

Published (Version of record) Open

1 Record Views

Title: 1778P Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
Creators: S.J. Freedland - Cedars-Sinai Medical Center
M.E. Gleave - University of British Columbia
U.F.F. De Giorgi - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
A. Rannikko - University of Helsinki
C. Pieczonka - Clinical Research Associates
S. Sridharan - Calvary Mater Newcastle Hospital
K. Brasso - Rigshospitalet
H. Woo - Sydney Adventist Hospital
A. Gomez Caamaño - Instituto de Investigación Sanitaria de Santiago
J. Saranchuk - CancerCare Manitoba
L.T. Nordquist - Urology Cancer Center and GU Research Network
U. Ferreira - Universidade Estadual de Campinas (UNICAMP)
Y. Tang - Pfizer (United States)
B. Rosbrook - Pfizer (United States)
G.P. Haas - Astellas Pharma (United States)
M. Rosales - Astellas Pharma (United States)
F. Zohren - Pfizer (United States)
N.D. Shore - Carolina Urologic Research Center
Publication Details: Annals of oncology, Vol.34, pp.S961-S961
Publisher: Elsevier Ltd
Identifiers: 991006262308002656
Academic Unit: Radiology
Language: English
Resource Type: Journal article